Evogene (TSE:EVGN – Free Report) had its price target cut by Desjardins from C$3.00 to C$2.00 in a report issued on Wednesday,BayStreet.CA reports. They currently have a buy rating on the stock.
Separately, Royal Bank of Canada set a C$1.00 price objective on Evogene and gave the stock a “sector perform” rating in a report on Wednesday.
Check Out Our Latest Analysis on EVGN
Evogene Price Performance
About Evogene
Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements.
Featured Articles
- Five stocks we like better than Evogene
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names
- ESG Stocks, What Investors Should Know
- 3 Stocks Getting Rare Double Upgrades From Analysts
- Business Services Stocks Investing
- This Banking Giant Just Got a $90 Price Target Upgrade
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
